STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : nnApril to June 2024 (compared to April to June 2023) nnNet sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.
STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET.
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this year’s...
STOCKHOLM, July 31, 2024 /PRNewswire/ -- During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the company's long-term incentive program issued in 2020, ESOP 2020 and Board of Directors program LTIP 2021. As of today, the total number of outstanding shares in Calliditas Therapeutics AB (publ) amounts to 59,941,465 ordinary shares. The number of votes in Calliditas Therapeutics AB (publ) as of today amounts to 59,941,465. The share capital has increased by SEK 14,455.12 from SEK 2,383,203.48 to SEK 2,397,658.60.
Calliditas Therapeutics’ slimmed-down, truncated and rethought primary biliary cholangitis (PBC) drug has hit its primary endpoint. But the biotech, which changed the midphase trial to cut costs, only saw a positive trend on liver stiffness and reported a higher rate of treatment-related dropouts on the study drug.
Calliditas Therapeutics AB (Calliditas) announces that its partner Viatris Pharmaceutical Japan G.K. (Viatris) has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN).